MCID: SCH011
MIFTS: 36

Schizotypal Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Schizotypal Personality Disorder

MalaCards integrated aliases for Schizotypal Personality Disorder:

Name: Schizotypal Personality Disorder 12 76 55 44 15 73
Schizotypal Personality 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10646
ICD10 33 F21
ICD9CM 35 301.22
MeSH 44 D012569
NCIt 50 C92632
SNOMED-CT 68 31027006
UMLS 73 C0036363

Summaries for Schizotypal Personality Disorder

Disease Ontology : 12 A personality disorder that involves a need for social isolation, anxiety in social situations, odd behavior and thinking, and often unconventional beliefs.

MalaCards based summary : Schizotypal Personality Disorder, also known as schizotypal personality, is related to schizophrenia and schizoaffective disorder. An important gene associated with Schizotypal Personality Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Metabolism and Long-term potentiation. The drugs Guanfacine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Schizotypal personality disorder (STPD) or schizotypal disorder is a mental disorder characterized by... more...

Related Diseases for Schizotypal Personality Disorder

Diseases related to Schizotypal Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 30.5 SULT4A1 PSAT1 COMT CACNA1C
2 schizoaffective disorder 29.9 SULT4A1 COMT
3 personality disorder 11.2
4 obsessive-compulsive disorder 10.4
5 borderline personality disorder 10.3
6 anorexia nervosa 10.2
7 cognitive function 1, social 10.1
8 autism 10.0
9 avoidant personality disorder 10.0
10 childhood-onset schizophrenia 10.0
11 depression 10.0
12 gilles de la tourette syndrome 10.0
13 anxiety 10.0
14 influenza 10.0
15 schizophrenia 5 9.9 EP300 COMT
16 mood disorder 9.8 COMT CACNA1C
17 disease of mental health 9.8 EP300 COMT

Graphical network of the top 20 diseases related to Schizotypal Personality Disorder:



Diseases related to Schizotypal Personality Disorder

Symptoms & Phenotypes for Schizotypal Personality Disorder

GenomeRNAi Phenotypes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.4 EP300
2 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.4 SULT4A1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.4 EP300 SULT4A1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.4 EP300
5 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.4 EP300
6 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.4 SULT4A1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.4 EP300
8 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.4 SULT4A1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.4 EP300
10 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.4 EP300
11 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.4 EP300

Drugs & Therapeutics for Schizotypal Personality Disorder

Drugs for Schizotypal Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
2 Neurotransmitter Agents Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Adrenergic alpha-Agonists Phase 4,Phase 2
4 Antihypertensive Agents Phase 4,Phase 2
5 Adrenergic Agonists Phase 4,Phase 2
6 Adrenergic Agents Phase 4,Phase 2,Not Applicable
7 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
8
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
9 Omega 3 Fatty Acid Phase 2, Phase 3
10 Protective Agents Phase 3,Phase 2
11 Expectorants Phase 3
12 Anti-Infective Agents Phase 3
13 N-monoacetylcystine Phase 3
14 Free Radical Scavengers Phase 3
15 Antioxidants Phase 3
16 Antiviral Agents Phase 3
17 Antidotes Phase 3
18 Respiratory System Agents Phase 3
19
Dopamine Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
20
Risperidone Approved, Investigational Phase 1, Phase 2,Not Applicable 106266-06-2 5073
21 Dihydrexidine Investigational Phase 2 123039-93-0
22 Dopamine agonists Phase 2,Not Applicable,Early Phase 1
23 Dopamine Agents Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Psychotropic Drugs Phase 1, Phase 2,Not Applicable
25 Antipsychotic Agents Phase 1, Phase 2,Not Applicable
26 Serotonin Agents Phase 1, Phase 2,Not Applicable
27 Serotonin Antagonists Phase 1, Phase 2,Not Applicable
28 Dopamine Antagonists Phase 1, Phase 2,Not Applicable
29 Tranquilizing Agents Phase 1, Phase 2,Not Applicable
30 Central Nervous System Depressants Phase 1, Phase 2,Not Applicable
31 Peripheral Nervous System Agents Phase 2,Not Applicable
32 Sympathomimetics Phase 2,Not Applicable
33 Autonomic Agents Phase 2,Not Applicable
34 Cardiotonic Agents Phase 2
35
Serotonin Investigational, Nutraceutical Phase 1, Phase 2,Not Applicable 50-67-9 5202
36
Oxytocin Approved, Vet_approved Phase 1 50-56-6 439302 53477758
37 Oxytocics Phase 1
38
Levodopa Approved Early Phase 1 59-92-7 6047
39
Benserazide Approved, Investigational Early Phase 1 322-35-0
40
Sertraline Approved Not Applicable 79617-96-2 68617
41
Adenosine Approved, Investigational 58-61-7 60961
42
Methamphetamine Approved, Illicit Not Applicable 537-46-2 10836
43
Aripiprazole Approved, Investigational Not Applicable 129722-12-9 60795
44 Antiparkinson Agents Early Phase 1
45 Dihydroxyphenylalanine Early Phase 1
46 Benserazide, levodopa drug combination Early Phase 1
47 Antidepressive Agents Not Applicable
48 Neurotransmitter Uptake Inhibitors Not Applicable
49 Serotonin Uptake Inhibitors Not Applicable
50 interferons

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
2 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
3 "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients" Recruiting NCT03149107 Phase 3 N-Acetylcysteine;Placebo
4 Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Unknown status NCT01466205 Phase 2 DAR-0100A;Placebo
5 Schizotypal Personality Disorder Risperidone Completed NCT02535156 Phase 1, Phase 2 Risperidone;Placebo
6 A D1 Agonist For Working Memory Completed NCT02507206 Phase 2 DAR 0-100A;Placebo
7 CRT-Guanfacine for SPD Completed NCT02524899 Phase 2 Guanfacine;Placebo
8 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
9 Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder Unknown status NCT00252044 Not Applicable Pergolide
10 Health Promotion on Young Adults With High Risk Disability for Mental Health Unknown status NCT01740167 Not Applicable
11 Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder Completed NCT00158028 Not Applicable Risperidone;Placebo
12 Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission Completed NCT03333369 Early Phase 1 200 mg levodopa/50 mg benserazide;Dextrose
13 Emotion Regulation in Trait Schizotypy Completed NCT03694574 Not Applicable
14 A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions Completed NCT00155519
15 Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis Completed NCT01619319 Not Applicable
16 Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms Completed NCT00169988 Not Applicable risperidone;sertraline-primary
17 Extended Specialized Assertive Intervention for First Episode Psychosis Completed NCT00914238 Not Applicable
18 Psychosis: Early Detection, Intervention and Prevention Completed NCT01597141 Not Applicable
19 Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study Completed NCT01269710
20 Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life Completed NCT02943330
21 Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample Recruiting NCT02800681
22 Neurofeedback Training for High Risk Psychosis Recruiting NCT03447548 Not Applicable
23 Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology Recruiting NCT03355781
24 Semantic and Syntactic Computerized Analysis of Free Speech Recruiting NCT03525054
25 Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis Active, not recruiting NCT00157313 Not Applicable
26 Early Detection and Intervention for Women At-risk of Psychosis Not yet recruiting NCT03751865 Not Applicable
27 Aripiprazole Treatment of the Prodrome Terminated NCT00169949 Not Applicable aripiprazole

Search NIH Clinical Center for Schizotypal Personality Disorder

Cochrane evidence based reviews: schizotypal personality disorder

Genetic Tests for Schizotypal Personality Disorder

Anatomical Context for Schizotypal Personality Disorder

MalaCards organs/tissues related to Schizotypal Personality Disorder:

41
Brain, Testes, Eye, Temporal Lobe, Caudate Nucleus, Pituitary, Cortex

Publications for Schizotypal Personality Disorder

Articles related to Schizotypal Personality Disorder:

(show top 50) (show all 355)
# Title Authors Year
1
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder. ( 29454512 )
2018
2
Enhanced mental imagery and intact perceptual organization in schizotypal personality disorder. ( 29131991 )
2018
3
Postural Sway Abnormalities in Schizotypal Personality Disorder. ( 30376125 )
2018
4
Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review. ( 30282970 )
2018
5
Multiple Frequency Bands Analysis of Large Scale Intrinsic Brain Networks and Its Application in Schizotypal Personality Disorder. ( 30123120 )
2018
6
Association of Schizoid and Schizotypal Personality disorder with violent crimes and homicides in Greek prisons. ( 30116288 )
2018
7
Schizotypal personality and semantic functioning: Revisiting category fluency effects in a subclinical sample. ( 30529320 )
2018
8
Poorer Integration of Local Orientation Information Occurs in Students With High Schizotypal Personality Traits. ( 30405458 )
2018
9
Validation of a Spanish version of the Schizotypal Personality Questionnaire (SPQ): Psychometric characteristics and underlying factor structure derived from a healthy university student sample. ( 30338773 )
2018
10
A reassessment of the higher-order factor structure of the German Schizotypal Personality Questionnaire (SPQ-G) in German-speaking adults. ( 30173038 )
2018
11
Deficits in context-dependent adaptive coding in early psychosis and healthy individuals with schizotypal personality traits. ( 30169587 )
2018
12
Sex differences in the association between childhood adversities and schizotypal personality traits. ( 30145298 )
2018
13
Poorer Search Efficiency in Healthy Young Adults With High Schizotypal Personality Traits. ( 30050472 )
2018
14
Schizotypal personality traits and social cognition are associated with childhood trauma exposure. ( 29923348 )
2018
15
The Network Structure of Schizotypal Personality Traits. ( 29684178 )
2018
16
Development and public release of a computerized adaptive (CAT) version of the Schizotypal Personality Questionnaire. ( 29625786 )
2018
17
The structure of schizotypal personality traits: a cross-national study. ( 28712364 )
2018
18
Psychometric properties of the Malay Schizotypal Personality Questionnaire: Measurement invariance and latent mean comparisons in Malaysian adults. ( 28677341 )
2018
19
Ventral Striatal Dysfunction and Symptom Expression in Individuals With Schizotypal Personality Traits and Early Psychosis. ( 27798223 )
2018
20
Reduced functional connectivity between bilateral precuneus and contralateral parahippocampus in schizotypal personality disorder. ( 28152990 )
2017
21
Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group. ( 28659980 )
2017
22
Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. ( 28347257 )
2017
23
Supervoxel-based statistical analysis of diffusion tensor imaging in schizotypal personality disorder. ( 28712990 )
2017
24
Dissociation of Brain Activation in Autism and Schizotypal Personality Disorder During Social Judgments. ( 29088456 )
2017
25
The Factor Structure of the Schizotypal Personality Questionnaire in Undergraduate and Community Samples. ( 26845533 )
2017
26
The Schizotypal Personality Questionnaire-Brief lacks measurement invariance across three countries. ( 28899612 )
2017
27
Dimensional Structure and Measurement Invariance of the Schizotypal Personality Questionnaire - Brief Revised (SPQ-BR) Scores Across American and Spanish Samples. ( 27749189 )
2017
28
Biological Motion Perception, Brain Responses, and Schizotypal Personality Disorder. ( 26790398 )
2016
29
Characterization of the Fiber Connectivity Profile of the Cerebral Cortex in Schizotypal Personality Disorder: A Pilot Study. ( 27303358 )
2016
30
Neurophysiological evidence of impaired self-monitoring in schizotypal personality disorder and its reversal by dopaminergic antagonism. ( 27330977 )
2016
31
Decreased fractional anisotropy values in two clusters of white matter in patients with schizotypal personality disorder: A DTI study. ( 27178397 )
2016
32
Neurological soft signs in Chinese adolescents with schizophrenia and schizotypal personality traits. ( 27432262 )
2016
33
Schizotypal personality questionnaire--brief revised (updated): An update of norms, factor structure, and item content in a large non-clinical young adult sample. ( 27086255 )
2016
34
Electrophysiological correlates of emotional meaning in context in relation to facets of schizotypal personality traits: A dimensional study. ( 26482112 )
2016
35
Chinese version of the Schizotypal Personality Questionnaire: Factor structure replication and invariance across sex. ( 26440145 )
2016
36
Measurement invariance of the Schizotypal Personality Questionnaire in Asian, Pacific Islander, White, and multiethnic populations. ( 26121382 )
2016
37
Sensory gating disturbances in the spectrum: similarities and differences in schizotypal personality disorder and schizophrenia. ( 25482574 )
2015
38
The melbourne assessment of Schizotypy in kids: a useful measure of childhood schizotypal personality disorder. ( 25629050 )
2015
39
Screening schizotypal personality disorder for detection of clinical high risk of psychosis in Chinese mental health services. ( 26165958 )
2015
40
Bifactor structure of the schizotypal personality questionnaire (SPQ). ( 26607431 )
2015
41
The validity of the Schizotypal Personality Questionnaire in a Greek sample: Tests of measurement invariance and latent mean differences. ( 26343467 )
2015
42
Assessing the construct validity of the Chinese-Version Schizotypal Personality Questionnaire-Brief on male and female undergraduate students. ( 25967647 )
2015
43
Ten-year stability of self-reported schizotypal personality features in patients with psychosis and their healthy siblings. ( 25882099 )
2015
44
Examination of the factor structure of the Schizotypal Personality Questionnaire among British and Trinidadian adults. ( 25699263 )
2015
45
Sleep spindles are related to schizotypal personality traits and thalamic glutamine/glutamate in healthy subjects. ( 25074975 )
2015
46
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. ( 25074637 )
2014
47
Visual-spatial working memory performance and temporal gray matter volume predict schizotypal personality disorder group membership. ( 24398009 )
2014
48
White Matter Abnormalities in Schizophrenia and Schizotypal Personality Disorder. ( 24962608 )
2014
49
Altered default mode network functional connectivity in schizotypal personality disorder. ( 25458858 )
2014
50
Schizotypal personality disorder: a current review. ( 24828284 )
2014

Variations for Schizotypal Personality Disorder

Expression for Schizotypal Personality Disorder

Search GEO for disease gene expression data for Schizotypal Personality Disorder.

Pathways for Schizotypal Personality Disorder

Pathways related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 CACNA1C COMT EP300 PSAT1 SULT4A1
2
Show member pathways
10.84 CACNA1C EP300

GO Terms for Schizotypal Personality Disorder

Biological processes related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to estrogen GO:0043627 8.62 COMT EP300

Molecular functions related to Schizotypal Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 8.92 COMT EP300 PSAT1 SULT4A1

Sources for Schizotypal Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....